Adaptive Biotechnologies’ president Rubinstein sells $2.37 million in ADPT stock

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices surge to two-week winning streak as Iran supply fears grip markets Wall Street posts three-week losing streak as Iran war batters sentiment Iran latest: Hegseth promises that U.S. military will reopen Strait of Hormuz Gold set for a two-week losing run as spiking oil prices spur inflation concerns (South Africa Philippines Nigeria) Adaptive Biotechnologies’ president Rubinstein sells $2.37 million in ADPT stock By Insider Trading Published 03/13/2026, 09:49 PM Adaptive Biotechnologies’ president Rubinstein sells $2.37 million in ADPT stock 0 ADPT 5.78% Adaptive Biotechnologies (NASDAQ:ADPT) President and COO Julie Rubinstein sold a total of 159,243 shares of common stock between March 11 and March 13, 2026, generating approximately $2.37 million. The sales occurred in a price range of $12.11 to $14.38 per share. The transactions come as the stock trades at $13.17, with the company carrying a market capitalization of $2.01 billion. Specifically, on March 11, Rubinstein sold 122,523 shares at a price of $13.17, totaling $1.61 million. Further sales on March 11 and 12, and 13 totaled 51,780 shares, with prices ranging from $12.63 to $14.08, generating approximately $760430. Additionally, Rubinstein exercised options to acquire 44,166 shares of Adaptive Biotechnologies stock at a price of $6.55 per share, for a total value of $289287. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.The insider sale occurs during a volatile period for the stock, which has dropped 11% over the past week despite posting an impressive 81% gain over the last year. According to InvestingPro analysis, ADPT currently appears overvalued relative to its Fair Value. For deeper insights, including 12 additional ProTips and comprehensive financial metrics, investors can access the full Pro Research Report available on InvestingPro . In other recent news, Adeptus Biotechnol...